RE: Q&A’s29 Sep 2020 16:51
https://www.valirx.com/wp-content/uploads/2020/09/VAL-September-Answers-final.pdf
We appreciate that theresults can be perceived as being very technical to investorsless familiar with theprocesses of clinical trials.Therefore,we willbe using interviews and videos to ensure the information isshared as widely as possible. All such media will be accessible on ourwebsite andwill be signposted viathe Company LinkedIn account.
Now that we have theheadlineresults from the VAL201 clinical trial, we will beprovidingupdatestoourindustry contacts and taking a decision on the best route forward forfurther development of VAL201.All possibilities will be explored with potential partners, including Joint Venture arrangements, whichcould see a partner funding a larger trial in a ValiRx subsidiary; out-licensing, which could see ValiRxreceive a combination of upfront, milestone and royalty payments; or an outright sale, which would seea one-off payment to ValiRx.As is typical in the biotech industry, we have been meeting with potential partnersthroughout thedevelopmentof VAL201 and judging their level of interest.We now intend to progress discussions withselected contacts.The clinical trial closedownprocess is ongoing, and full details of the results are still being assembled intothe Clinical Study Report. When this report is complete,whichisexpectedduring Q4 2020, this will besubmitted to the regulators, the MHRA, as part of the formal trial process. At this time, public databases,such as that held on clinicaltrials.gov will also be updated. If any items of particular general interestemerge from the data at this stage, they will immediately be released via a Company announcement,anddisseminatedthroughpeerreviewedpublicationandpresentationsasappropriate.
Sign In
Follow the stocks
